Murphy G M, Logan R A, Lovell C R, Morris R W, Hawk J L, Magnus I A
Br J Dermatol. 1987 Apr;116(4):531-8. doi: 10.1111/j.1365-2133.1987.tb05874.x.
A double-blind controlled trial of low-dose prophylactic oral psoralen photochemotherapy (PUVA) and ultraviolet-B (UVB) irradiation therapy was undertaken from April to September 1983 in 42 patients with polymorphic light eruption (PLE). Patients were randomly allocated to three groups, PUVA with oral 8-methoxypsoralen (8-MOP), UVB with oral placebo, and control low-dose UVA with oral placebo. The initial dose given to each active treatment group was a third of the predetermined minimal phototoxic or erythema dose, followed three times weekly for 6 weeks by doses incremented by an eighth on each occasion in the PUVA group and by a seventh in the UVB group. Ultraviolet radiation exposure was monitored throughout with polysulphone film lapel badges. Patients recorded their symptoms on a visual analogue scale. Symptoms of rash and itch in patients treated with PUVA and UVB were significantly less affected by increasing exposure to ultraviolet radiation than were these symptoms in control patients.
1983年4月至9月,对42例多形性日光疹(PLE)患者进行了低剂量预防性口服补骨脂素光化学疗法(PUVA)和紫外线B(UVB)照射疗法的双盲对照试验。患者被随机分为三组,分别为口服8-甲氧基补骨脂素(8-MOP)的PUVA组、口服安慰剂的UVB组和口服安慰剂的对照低剂量UVA组。每个活性治疗组的初始剂量为预定最小光毒性或红斑剂量的三分之一,随后在PUVA组中每周三次,持续6周,每次剂量增加八分之一,在UVB组中每次剂量增加七分之一。整个过程中使用聚砜薄膜翻领徽章监测紫外线辐射暴露情况。患者用视觉模拟量表记录症状。与对照组患者相比,接受PUVA和UVB治疗的患者皮疹和瘙痒症状受紫外线辐射暴露增加的影响明显较小。